Bone Biologics Corporation
BBLG
$0.55
-$0.01-1.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.08% | 8.68% | 4.12% | -8.59% | -8.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.68% | -31.06% | -23.32% | 6.08% | -13.35% |
| Operating Income | 28.68% | 31.06% | 23.32% | -6.08% | 13.35% |
| Income Before Tax | 31.50% | 32.97% | 24.40% | 4.70% | 17.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.50% | 32.97% | 24.40% | 4.70% | 17.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.50% | 32.97% | 24.40% | 4.70% | 17.56% |
| EBIT | 28.68% | 31.06% | 23.32% | -6.08% | 13.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 92.39% | 89.49% | 86.58% | 84.26% | 65.66% |
| Normalized Basic EPS | 84.14% | 80.48% | 78.73% | 75.63% | 81.92% |
| EPS Diluted | 92.39% | 89.49% | 86.58% | 84.26% | 65.66% |
| Normalized Diluted EPS | 84.14% | 80.48% | 78.73% | 75.63% | 81.92% |
| Average Basic Shares Outstanding | 300.72% | 315.79% | 363.60% | 389.30% | 301.54% |
| Average Diluted Shares Outstanding | 300.72% | 315.79% | 363.60% | 389.30% | 301.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |